AbbVie: A Pharmaceutical Giant with a Terrific Track Record for Long-Term Returns
ByAinvest
Thursday, Dec 4, 2025 9:18 am ET1min read
ABBV--
AbbVie, a pharmaceutical giant, has a strong track record of beating the S&P 500 returns since its split from Abbott Laboratories in 2013. The company protected its Humira medicine from biosimilars, innovated with new products, resorted to acquisitions, and significantly grew its dividends. With a deep pipeline of products and a history of raising payouts for over 50 years, AbbVie is a Dividend King that can continue to help investors establish a solid foundation for their financial future.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet